Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury
Author
dc.contributor.author
Toro, Luis
Author
dc.contributor.author
Barrientos, Víctor
Author
dc.contributor.author
León, Pablo
Author
dc.contributor.author
Rojas, Macarena
Author
dc.contributor.author
González, Magdalena
Author
dc.contributor.author
González Ibáñez, Álvaro
Author
dc.contributor.author
Illanes, Sebastián E.
Author
dc.contributor.author
Sugikawa, Keigo
Author
dc.contributor.author
Abarzu, Néstor
Author
dc.contributor.author
Bascuñán, César
Author
dc.contributor.author
Arcos, Katherine
Author
dc.contributor.author
Fuentealba, Carlos
Author
dc.contributor.author
Tong, Ana María
Author
dc.contributor.author
Elorza, Alvaro A.
Author
dc.contributor.author
Pinto, María Eugenia
Author
dc.contributor.author
Alzamora Miranda, Rodrigo
Author
dc.contributor.author
Romero, Carlos
Author
dc.contributor.author
Michea Acevedo, Luis
Admission date
dc.date.accessioned
2018-08-23T13:05:57Z
Available date
dc.date.available
2018-08-23T13:05:57Z
Publication date
dc.date.issued
2018
Cita de ítem
dc.identifier.citation
Kidney International Volumen: 93 Número: 5 Páginas: 1131-1141
es_ES
Identifier
dc.identifier.other
10.1016/j.kint.2017.11.018
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/151174
Abstract
dc.description.abstract
It is accepted that osteoblasts/osteocytes are the major source for circulating fibroblast growth factor 23 (FGF23). However, erythropoietic cells of bone marrow also express FGF23. The modulation of FGF23 expression in bone marrow and potential contribution to circulating FGF23 has not been well studied. Moreover, recent studies show that plasma FGF23 may increase early during acute kidney injury (AKI). Erythropoietin, a kidney-derived hormone that targets erythropoietic cells, increases in AKI. Here we tested whether an acute increase of plasma erythropoietin induces FGF23 expression in erythropoietic cells of bone marrow thereby contributing to the increase of circulating FGF23 in AKI. We found that erythroid progenitor cells of bone marrow express FGF23. Erythropoietin increased FGF23 expression in vivo and in bone marrow cell cultures via the homodimeric erythropoietin receptor. In experimental AKI secondary to hemorrhagic shock or sepsis in rodents, there was a rapid increase of plasma erythropoietin, and an induction of bone marrow FGF23 expression together with a rapid increase of circulating FGF23. Blockade of the erythropoietin receptor fully prevented the induction of bone marrow FGF23 and partially suppressed the increase of circulating FGF23. Finally, there was an early increase of both circulating FGF23 and erythropoietin in a cohort of patients with severe sepsis who developed AKI within 48 hours of admission. Thus, increases in plasma erythropoietin and erythropoietin receptor activation are mechanisms implicated in the increase of plasma FGF23 in AKI.